Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

M. Sticherling*, U. Mrowietz, M. Augustin, D. Thaçi, N. Melzer, C. Hentschke, J. Kneidl, C. Sieder, K. Reich

*Korrespondierende/r Autor/-in für diese Arbeit
49 Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial“. Zusammen bilden sie einen einzigartigen Fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology